Interventional Study on DEterminants and Factors of Physical ACtivity After Treatments in Oncology (DEFACTO2)

Benefits of physical activity (PA) as supportive care in cancer have been widely demonstrated by the scientific community. However, survivors who have completed chemo-radio-immunotherapy treatments doesn't achieve PA recommendations on average. This reinforces the need to identify factors influencing PA level, and to propose a multilevel model (macro-, meso-, micro-level) to understand better what facilitates the adoption and maintenance of active behaviour and what hinders it. To date, there is no ecological model in France explaining this behaviour in the post-treatment phase of breast, colorectal, prostate, and lung cancers. From this initial model, we seek to design an educational and motivational intervention in PA.

Thus, the investigators propose to test the feasibility of implementing an individualized program to increase and maintain level of physical activity and to decrease sedentary behaviours in physically inactive cancer survivors. This program is based through and identification of barriers and facilitators of an active lifestyle among this population.

Study Overview

• Status: Recruiting
• Conditions: Breast Cancer; Lung Cancer; Prostate Cancer; Colo-rectal Cancer
• Intervention / Treatment: Behavioral: Physical activity program

Detailed Description

In 2008, 3 million French people had experienced cancer in the last 15 years, compared to 18 million in 2022. Post-treatment marks a break with the intensive care pathway. It frequently leads to changes in the lifestyle of these patients. During this period, behaviors conducive to maintaining their state of health remain important.

Among these behaviors, Physical Activity (PA) is an integral part and brings many post-treatment benefits. Despite the evidence of PA benefits in adult cancer survivors who have completed chemo-radio-immunotherapy treatments, the majority of those with good prognosis cancer are insufficiently active. Patient survival tends to increase by 20% thanks to scientific progress and the improvement of cancer management. At the same time, patients experience adverse effects for an extended period after cancer treatment. It would take an average of 10 to 15 years to note a decrease in the psychological, physical, professional, and socio-economic repercussions of cancer. These repercussions do not totally disappear over time. We have a particular interest in this post-treatment period, where the end of treatments marks a break within the "clinical pathway". The patient then joins the "care pathway" where he/she needs to have an autonomous management of his/her health behaviour.

The study of factors - clinical, psychological, cognitive, behavioural, social, or even linked to the clinical pathway and the geographical environment - involved in regular PA practice with breast, prostate, colorectal, or lung cancer survivors, would allow us an overview of what shapes a complex behaviour like PA.

In view of these needs to better understand and act on the complex behaviour of active lifestyle, the main objective of our research is to design, implement, and evaluate an individualised educational and motivational program, constructed from an explanatory ecological model. The educational and motivational program thus conceived will help in supporting good prognosis and physically inactive cancer survivors (breast, colorectal, prostate, or lung cancers) in initiation and maintenance of their PA.

Deployment of this interventional approach will provide more support to cancer survivors at the end of their treatment at a national level while considering the specificities of healthcare fields. To consider these variety, transferability criteria will be taken into account.

Thus, the investigators propose to test the feasibility of implementing an individualized program to increase and maintain level of physical activity and to decrease sedentary behaviours in physically inactive cancer survivors. This program is based through and identification of barriers and facilitators of an active lifestyle among this population.

• Study Type: Interventional
• Enrollment (Anticipated): 150
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Albane AA Aumaitre, PhD Student; Phone Number: 0033616883160; Email: albane.au@gmail.com
• Study Contact Backup: Name: Aude Marie AF Foucaut; Phone Number: 0033148387642; Email: audemarie.foucaut@sorbonne-paris-nord.fr

Study Locations

• France
  • Bobigny, France, 93017
    • Recruiting
    • Laboratoire Educations et Promotion de la Santé UR3412
    • Contact: Albane AA Aumaitre, PhD Student; Phone Number: 0033616883160; Email: albane.au@gmail.com
    • Contact: Aude Marie AF Foucaut; Phone Number: 0033148387642; Email: audemarie.foucaut@sorbonne-paris-nord.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• 18 years ≤ age < 75 years
• survivors of primary non-metastatic breast, lung, prostate or colorectal cancer (stage I, II or III and primary, second and relapse included)
• 3 weeks to 20 years post-treatment (surgery, chemotherapy, radiation therapy and/or immunotherapy) not including hormonal therapy
• Whose ability to participate in the APA intervention has been certified by a medical certificate issued by physician
• Availability and willingness to invest in the DEFACTO study during the program (3 months) and during the post-program follow-up (12 months)
• Participating, on average, in no more than 150 minutes of moderate physical activity or no more than 75 minutes of vigorous activity per week
• Average at least 6 hours a day of sedentary behaviours
• Able to read, understand and complete questionnaires in French
• Able to use connected device (Vivosmart4®) and to perform simple operating actions (press a button, recharge the battery)
• possessing a smartphone which can download Garmin Connect application ®
• Able to walk unassisted
• French speaking and living in France
• having signed the consent form

Exclusion Criteria:

• Current evidence of metastatic disease
• Having an absolute contraindication by a physician to practice PA
• Using treatments that influence blood pressure, cardiotoxic drugs, painkillers (morphinics);
• Using cane or walking aid
• Deprived of liberty by judicial or administrative decision
• Person under guardianship or curatorship
• Pregnancy and/or lactating women
• Being diagnosed of any cardiac abnormalities

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Intervention; Feasibility group. Single group (intervention group) will be given access to the DEFACTO intervention for twelve-weeks.	Behavioral: Physical activity program; The single group will access to the twelve-week DEFACTO program containing one adapted physical activity session, two discussion group sessions and several motivational interviewing; Other Names: Motivational Interviewing; Discussion group; Adapted physical activity

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change of physical activity (connected device)	Average daily steps, distance traveled, floors climbed, heart rate, cumulative duration of activities of moderate and vigorous intensities using VIVOSMART4® (Garmin)	One week before initiation of DEFACTO intervention, during the intervention and intervention at Month 3 and Month 6 and Month 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change of physical activity by the Global Physical Activity Questionnaire (GPAQ)	Change of physical activity evaluated by the GPAQ questionnaire, at baseline (at inclusion), and at the completion of intervention (12 weekends after the start of the intervention)	At baseline (at inclusion), and at the completion of intervention (12 weekends after the start of the intervention)
Assessment of life quality	Assessment by using the Short-Form 12 questionnaire (SF-12) Life quality scores calculation	At Baseline (at inclusion), and at the completion of intervention (12 weekends after the start of the intervention)
Assessment of Health literacy level	Assessment by using a single question concerning the need to resort refer to a health professional to understand health information	At Baseline (at inclusion), and at the completion of intervention (12 weekends after the start of the intervention)
Assessment of Knowledge about PA and its link with cancer	Assessment by using specific questions of the Cancer Exercise Stereotypes Scale	At Baseline (at inclusion), and at the completion of intervention (12 weekends after the start of the intervention)
Physical activity barriers	Assessment by using the "General determinants of PA" questionnaire. This tool examines 7 areas: 1) Lack of time; 2) Social influences; 3) Lack of energy; 4) Lack of willingness; 5) Fear of hurting yourself; 6) Lack of skill sets; 7) Lack of resources	At Baseline (at inclusion), and at the completion of intervention (12 weekends after the start of the intervention)
Transtheorical model's variables related to physical activity	Assessment by using the "Stages of change" questionnaire, "Processes of change (POC)" questionnaire, "decisional balance" questionnaire, and "self-efficacy" questionnaire.	At Baseline (at inclusion), and at the completion of intervention (12 weekends after the start of the intervention)
Motivation to physical activity pratice	Types of motivation based on self-determination theory, assessment by using the Motivation Scale for by Physical Activity for Health Purposes	At Baseline (at inclusion), and at the completion of intervention (12 weekends after the start of the intervention)

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Weight	in kilograms (weight and height will be combined to report BMI in kg/m^2)	At Baseline (at inclusion)
Height	in centimeters (height and weight will be combined to report BMI in kg/m^2)	At Baseline (at inclusion)
Date of cancer diagnosis	(month/year)	At Baseline (at inclusion)
Tumor location and cancer recurrence or second primary cancer	(breast, colorectal, lung or prostate)	At Baseline (at inclusion)
Stage of cancer	(I, /II, or /III)	At Baseline (at inclusion)
Type of treatment	(chemotherapy, radiation therapy, immunotherapy, hormonotherapy)	At Baseline (at inclusion)
Clinical data	Body Mass Index (BMI, kg/m^2), date of diagnosis (month/year), tumour location (breast, colorectal, lung or prostate), stage of cancer (I, /II, or /III), cancer recurrence or second primary cancer, type of treatment, date on the treatment end (chemotherapy, radiation therapy, immunotherapy, hormonotherapy + month/year); (close-ended questions)	At Baseline (at inclusion)
Date on the treatment end	(month/year)	At Baseline (at inclusion)
Socio-demographic variables	Educational qualifications, economic class-status, current professional situation, household type, habitat type, geographical environment (rural or /urban); (close-ended questions)	At Baseline (at inclusion)

Collaborators and Investigators

• Sponsor: Université Sorbonne Paris Nord
• Collaborators: Ligue contre le cancer, France; Garmin International; Stimulab
• Investigators: Principal Investigator: Aude-Marie AF Foucaut, Université Sorbonne Paris Nord, Laboratoire Educations et Promotion de la Santé UR3412

Study record dates

Study Major Dates

• Study Start (Actual): March 29, 2022
• Primary Completion (Anticipated): July 1, 2023
• Study Completion (Anticipated): December 1, 2023

Study Registration Dates

• First Submitted: April 11, 2022
• First Submitted That Met QC Criteria: April 26, 2022
• First Posted (Actual): May 2, 2022

Study Record Updates

• Last Update Posted (Actual): May 9, 2023
• Last Update Submitted That Met QC Criteria: May 8, 2023
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colorectal Neoplasms; Rectal Neoplasms
• Other Study ID Numbers: 2021-A01570-41

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No